Overview

MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults

Status:
Completed

Trial end date:
2006-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare the efficacy of a flexible dose of Symbicort (budesonide/formoterol) with conventional stepwise best standard treatment in patients with persistent asthma.

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate